How do mononeuropathy and polyneuropathy differ in terms of clinical presentation, underlying causes, diagnostic evaluation, and treatment?

Mononeuropathy versus Polyneuropathy: Key Clinical Distinctions

Mononeuropathy affects a single nerve and typically results from focal injury (compression, trauma, entrapment), while polyneuropathy involves multiple nerves in a symmetric, distal distribution and usually stems from systemic metabolic, toxic, or inflammatory causes.

Clinical Presentation

Mononeuropathy

• Pattern: Asymmetric, affecting one specific nerve territory
• Distribution: Localized to the anatomical course of a single nerve (e.g., median nerve in carpal tunnel syndrome, ulnar nerve at elbow, peroneal nerve at fibular head) 1
• Symptoms: Focal numbness, weakness, or pain in the distribution of the affected nerve
• Most common: Carpal tunnel syndrome (prevalence 5%, incidence 1-2 per 1,000 person-years) 2

Polyneuropathy

• Pattern: Symmetric, bilateral, distal-to-proximal ("stocking-glove" distribution)
• Distribution: Begins in feet, progresses proximally; hands affected later 3
• Symptoms: Numbness, paresthesias, burning pain, weakness starting distally
• Prevalence: ~1% general population, rising to 7% in those over 65 years 2

Critical distinction: Mononeuropathy multiplex presents as multiple individual nerve lesions in an asymmetric pattern—this is distinct from both simple mononeuropathy and polyneuropathy, and strongly suggests vasculitis, leprosy, or infiltrative disease 3, 4.

Underlying Causes

Mononeuropathy

• Mechanical: Compression, entrapment (most common)
• Trauma: Direct nerve injury
• Ischemia: Focal vascular compromise
• Infection: Localized (e.g., leprosy affecting specific nerves) 3

Polyneuropathy

The diagnostic workup should prioritize the highest-yield causes 5:

1. Diabetes mellitus (most common—blood glucose elevated in ~11% of DSP cases)
2. Vitamin B12 deficiency (low in ~3.6%, but metabolites reveal deficiency in 5-10% with "low-normal" B12 levels of 200-500 pg/dL)
3. Monoclonal gammopathy (abnormal in ~9% via immunofixation electrophoresis)
4. Alcohol abuse
5. Toxic medications/agents
6. Hereditary neuropathies (CMT variants)
7. Autoimmune/inflammatory (CIDP, vasculitis)

Diagnostic Evaluation

Mononeuropathy

• Clinical examination: Identify specific nerve territory involvement
• Electrodiagnostic studies: Focal slowing or conduction block at the site of compression 3
• Imaging: Neuromuscular ultrasound or MR neurography to visualize nerve pathology 1

Polyneuropathy

Electrodiagnostic studies are essential to categorize the neuropathy 3:

• Axonal pattern: Reduced amplitudes, minimal slowing, denervation on EMG (most common)
• Demyelinating pattern: Prolonged latencies, marked slowing, temporal dispersion, conduction block
  • Uniform demyelination → hereditary
  • Non-uniform demyelination → acquired (CIDP, GBS)

Laboratory screening panel for all polyneuropathy patients 5:

• Blood glucose (highest yield)
• Serum B12 with metabolites (methylmalonic acid ± homocysteine)
• Serum protein immunofixation electrophoresis (more sensitive than SPEP for detecting monoclonal proteins)
• Complete blood count, ESR, comprehensive metabolic panel
• Thyroid function tests

Additional testing based on clinical phenotype:

• Glucose tolerance test: Consider in distal sensory polyneuropathy without overt diabetes (25-36% have impaired glucose tolerance) 5
• Autonomic testing: For suspected autonomic neuropathy or small fiber sensory polyneuropathy (SFSN) 6
• Skin biopsy: To quantify intraepidermal nerve fiber density in SFSN 6
• Genetic testing: For hereditary phenotype (CMT1A duplication most common) 5
• Nerve biopsy: Reserved for suspected vasculitis, amyloidosis, or atypical CIDP 6

Important caveat: Laboratory tests alone have only 37% diagnostic yield; interpretation requires clinical context 5. The combination of history, examination, electrodiagnostics, and targeted labs yields etiologic diagnosis in 74-82% of cases 5.

Fiber Type Involvement

Large Fiber Neuropathy

• Loss of vibration and joint position sense
• Sensory ataxia
• Areflexia
• Detected by standard nerve conduction studies 3

Small Fiber Neuropathy

• Impaired pain and temperature sensation
• Burning pain, allodynia, erythromelalgia
• Autonomic dysfunction (sweating abnormalities, circulatory instability)
• Normal nerve conduction studies (requires autonomic testing or skin biopsy for diagnosis) 6, 3

Treatment Approach

Mononeuropathy

• Conservative management: Splinting, activity modification
• Surgical decompression for refractory cases
• Address underlying cause (e.g., diabetes control)

Polyneuropathy

Treatment targets the underlying etiology:

• Diabetes: Glycemic control (prevents progression but doesn't reverse established neuropathy)
• B12 deficiency: Replacement therapy
• Monoclonal gammopathy: Hematology referral for MGUS vs. malignancy workup
• Immune-mediated: Immunotherapy (corticosteroids, IVIG, plasmapheresis for CIDP/GBS)
• Vasculitis: Aggressive immunosuppression (cyclophosphamide + corticosteroids) 4

Symptomatic pain management for painful polyneuropathy 7:

• First-line: Duloxetine, pregabalin, gabapentin, or amitriptyline
• Combination therapy for inadequate monotherapy response
• Refractory cases: Capsaicin 8% patches or spinal cord stimulation

Critical pitfall: Approximately 20-25% of chronic polyneuropathies remain cryptogenic despite thorough evaluation 2, 8. These are typically slowly progressive axonal sensory polyneuropathies with relatively benign prognosis, but require exclusion of treatable causes first.

Impact on Function and Quality of Life

Polyneuropathy causes significantly greater functional impairment than mononeuropathy 9. Patients with polyneuropathy demonstrate worse hand dexterity, functional performance, and quality of life scores across multiple domains (aesthetics, satisfaction, diabetes control, sexual function, energy, mobility) compared to those with mononeuropathy or no neuropathy. This underscores the importance of early diagnosis and aggressive management of systemic causes.